
pmid: 32759176
While promising, convalescent plasma remains experimental and is not proven effective for COVID-19. In addition, many questions remain regarding the accuracy and predictive value of antibody testing of donors and patients, optimal donor selection, optimal timing, and selection of patients most likely to benefit. Until these questions are answered, convalescent plasma should ideally be used in the context of well-designed clinical trials.
Clinical Trials as Topic, Clinical Laboratory Techniques, SARS-CoV-2, Patient Selection, Pneumonia, Viral, Immunization, Passive, COVID-19, Reproducibility of Results, Risk Assessment, Donor Selection, Time-to-Treatment, Betacoronavirus, COVID-19 Testing, Treatment Outcome, Predictive Value of Tests, Humans, Coronavirus Infections, Pandemics, COVID-19 Serotherapy
Clinical Trials as Topic, Clinical Laboratory Techniques, SARS-CoV-2, Patient Selection, Pneumonia, Viral, Immunization, Passive, COVID-19, Reproducibility of Results, Risk Assessment, Donor Selection, Time-to-Treatment, Betacoronavirus, COVID-19 Testing, Treatment Outcome, Predictive Value of Tests, Humans, Coronavirus Infections, Pandemics, COVID-19 Serotherapy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 4 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
